Low alanine aminotransferase activity gene variant in a Siberian Husky with copper-associated hepatopathy
BMC Veterinary Research volume 19, Article number: 111 (2023)
Alanine aminotransferase (ALT) is commonly used as a marker of hepatocellular injury. Increased serum ALT activity due to hepatocyte injury occurs in copper-associated hepatopathy (CuCH) and other necroinflammatory liver conditions. Blood ALT concentrations are frequently used to monitor therapy in cases of CuCH. Low serum ALT activities have been associated with an allele at a CFA13 locus.
A 9-year-old female spayed Siberian Husky was diagnosed with CuCH (hepatic copper dry weight 2680 µg/g [normal, 120–400 µg/g; toxic, > 1500 µg/g]) and a normal ALT (78 U/L; reference range, 10–125 U/L). Mild hepatocellular necrosis was evident histologically. Genetic testing (Embark) revealed that the dog was heterozygous for the low ALT activity gene allele.
This case report illustrates the clinical implications for diagnosing and managing necroinflammatory liver disease such as CuCH in dogs with a low ALT activity genotype.
Serum alanine aminotransferase (ALT) activity is commonly used as a biomarker for hepatocellular injury. In dogs, ALT is highly specific for hepatocellular necrosis and is present predominantly in the cytosol [1, 2]. Various hepatic necroinflammatory conditions can lead to hepatocellular necrosis, including infectious, neoplastic, or chronic inflammatory diseases.
Copper-associated hepatopathy (CuCH) is the most common toxic-injury-induced chronic hepatopathy in dogs [3, 4]. Contributing factors include genetic predisposition and dietary copper levels. Predisposed breeds include the Bedlington Terrier, Dalmatian, Labrador Retriever, Doberman Pinscher, and West Highland White Terrier, but CuCH can occur in any breed. The genetic basis of CuCH in two breeds is described and associated with cellular copper trafficking mechanisms. The Bedlington Terrier was the first breed where CuCH was extensively studied, and a COMMD1 (MURR1) mutation is responsible for CuCH in this breed [5, 6]. More recently, CuCH has been increasingly recognized in the Labrador Retriever, where variants in the ATP7B and ATP7A genes have been implicated as a predisposing or protective factor, respectively, for this breed’s CuCH . Hepatic copper accumulation (typically greater than 1000 µg/g liver dry weight [dw]) induces oxidant injury, manifested by histological morphologic changes or increased serum ALT activity .
Lower serum ALT activity has been associated with an allele (A) at a CFA13 locus in dogs of many breeds, although allele causality has not been proven . In healthy dogs, homozygous AA and heterozygous AG dogs had lower ALT activities than dogs homozygous for the GG allele. Dogs that were AA homozygous with liver disease or injury had the lowest ALT activities, often in the reference range. In a recent study evaluating genetic traits in northern working breeds, the most common health trait identified by a commercial genetic testing panel in Alaskan Sled Dogs and Siberian Huskies was lower ALT activity . We present a case of a Siberian Husky with the low ALT activity trait on Embark testing with severe hepatic copper accumulation and histologically documented hepatocellular necrosis.
A 9-year-old female spayed Siberian Husky weighing 32.1 kg was presented to an emergency service at a veterinary specialty hospital for a decreased appetite of a few days duration in January of 2022. The dog’s only previously diagnosed active medical problem was hypothyroidism, diagnosed one year prior. The dog’s only medical treatments at presentation included levothyroxine (0.6 mg orally twice daily). She was being fed a Kirkland brand adult dry dog food. Physical examination revealed no abnormalities. During this initial evaluation, blood was drawn for a complete blood count, which did not reveal any abnormalities. A serum chemistry panel (Table 1) showed an elevated alkaline phosphatase (ALP) activity (438 U/L; reference range, 23–212 U/L) and was otherwise normal (ALT 78 U/L; reference range, 10–125 U/L).
Thoracic radiographs were unremarkable. Abdominal ultrasonography revealed an 11 × 8 cm mixed echogenic mass originating from the body of the spleen. The mass was expansile and associated with hyperechoic surrounding mesentery, raising concern for a recent bleeding event. The liver size was at the lower end of normal, with a homogenously isoechoic parenchyma.
A splenectomy and liver biopsies were performed the following day. Histopathology of the spleen was consistent with nodular lymphoid hyperplasia with congestion, hemorrhage, and occasional necrosis. Histologic evaluation of the liver revealed mild, diffuse vacuolar hepatopathy and occasional midzonal individual hepatocellular necrosis (Fig. 1A) with moderate multifocal nodular histiocytic and less lymphocytic and neutrophilic infiltrates. Minimal multifocal lymphoplasmacytic portal hepatitis was present with mild portal fibrosis and bile duct hyperplasia. Marked subjective centrilobular to midzonal hepatocellular copper accumulation was suspected on hematoxylin and eosin stained sections. Rhodanine staining revealed large numbers of centrilobular to midzonal hepatocytes with moderate to frequent large amounts of cytoplasmic copper (Fig. 1B&C). Quantitative copper testing (Colorado State University) confirmed a markedly elevated hepatic copper concentration of 2680 µg/g dw (normal, 120–400 µg/g dw; toxic, > 1500 µg/g dw).
The dog was presented to the Internal Medicine Service at IronHorse VetCare for further evaluation of a copper-associated hepatopathy in April 2022. A serum chemistry panel (Table 1) was re-evaluated, revealing a persistently elevated ALP (424 U/L; reference range, 5-160 U/L) and a normal ALT (89; reference range, 18–121 U/L). Paired serum bile acid concentrations were within normal limits. The dog was transitioned to a low copper (approximately 1 mg/1000 kcal) veterinary therapeutic hepatic diet with ~ 2 tablespoons of cottage cheese or chicken breast per cup or can of diet provided for additional protein. D-penicillamine treatment was prescribed at 300 mg (10 mg/kg) by mouth once daily for 14 days, then increased in frequency to twice daily.
The dog’s normal ALT activity in the face of severe copper accumulation and hepatocellular necrosis prompted genetic screening through a commercial laboratory that tests for the A allele previously described  as associated with low ALT activity (Breed + Health Test, Embark Veterinary, Inc., 320 Summer Street, Floor 6, Boston, MA 02210, https://embarkvet.com/). Results disclosed that the dog had one copy of the low ALT activity trait variant, indicating she was heterozygous AG.
Six months (October 2022) after starting D-penicillamine, the dog was re-evaluated at another veterinary hospital. The dog’s ALT remained normal (43 U/L, reference range 18–121 U/L), although it was now approximately half of the previously measured values (Table 1). The ALP was persistently elevated (371, reference range 5-160 U/L). The dog’s owner reported that she remains clinically well with a normal appetite and energy level. Penicillamine was discontinued, and a low copper diet was recommended to be continued indefinitely.
Discussion and conclusions
This case report illustrates the clinical impact of low ALT activity gene variants in dogs and the interpretation of routine biochemical testing. Patients with this trait may be underdiagnosed or diagnosed later in the course of necroinflammatory hepatic conditions. Additionally, monitoring ALT in these cases may not be as suitable a surrogate biomarker for hepatocellular injury as it is in dogs with normal ALT activity genotypes.
Evidence of hepatic damage in CuCH typically manifests as increased serum ALT activity, histologic changes, or both when hepatic copper concentrations exceed 1000 µg/g dw and almost always occurs at concentrations over 1500 µg/g dw. In this case, ALT concentrations were normal despite the histologic presence of multifocal inflammation and necrotic hepatocytes. At least two possibilities for this observation exist. First, this degree of necroinflammatory disease was insufficient to result in increased serum ALT activity in this dog and unrelated to the CFA13 locus genotype. The second possibility is that this dog’s genotype contributed to its discordantly normal serum ALT activity. The normal serum AST activities measured in this case may support the former assertion. However, in one study, the median AST:ALT ratios in dogs with hepatic fibrosis and necroinflammatory changes were approximately 0.25 . Thus, dogs with mild ALT increases would frequently have normal serum AST activities. The original study documenting the low ALT activity gene variant did not include serum AST in their model. In the primary author’s dissertation defense, AST was analyzed, and they found the opposite trend compared to ALT between AST activities and the A allele at the CFA13 locus. Interestingly, however, many heterozygous dogs with hepatic disease had AST activities in the normal range . It is impossible to irrefutably explain this patient’s normal ALT activity by its genotype alone. However, given the histologic findings and the reduction in ALT after treatment, we suspect the dogs’ low ALT activity genotype is the most likely explanation for this patient’s discordant clinical pathology results and liver histologic lesions.
Discordance and variability between histologic disease severity, serum hepatic enzyme activities, or hepatic copper concentrations have been documented previously in canine liver diseases [3, 10, 12,13,14]. Chronic hepatitis can be present in dogs with normal serum liver enzyme activities, despite being the most common biochemical abnormality in dogs with chronic hepatitis . In two studies including dogs with CuCH, ALT activity was increased in all cases where it was measured; however, hepatic copper concentrations were not measured, precluding more direct comparisons [15, 16]. This case represents an additional challenge as serum ALT activity is frequently used as a surrogate marker for hepatocellular injury to guide therapy in dogs with CuCH . Serum concentrations of some microRNAs, such as miR-122, are increased in dogs with hepatocellular injury [17,18,19,20]. MicroRNA biomarkers may be helpful in screening and monitoring cases of chronic hepatitis with low ALT activity genotypes but, unfortunately, are not available for routine diagnostic testing. This dog’s increased ALP activity aligns with the histologically observed vacuolar changes and may be partly reactive to CuCH. Therefore, monitoring ALP activity may provide some metric of treatment response, although it may be less specific for copper chelation efficacy than ALT. Ultimately, liver biopsy is the gold standard measure of copper chelation efficacy. However, treatment success is often gauged by ALT monitoring. Thus, there may be a greater need to consider post-treatment liver biopsy to monitor chelation efficacy in dogs with low ALT activity genotypes.
This case illustrates the potential impact of genotype on the interpretation of serum ALT activity in dogs with necroinflammatory hepatic diseases. Genetic testing may guide diagnostic and monitoring decisions that frequently rely on ALT as a surrogate marker of hepatocellular injury. Further investigation of ALT allele variants in dogs with necroinflammatory hepatic disease may help explain some of the discordance observed between the histologic severity of hepatocellular injury and serum ALT activities. Prospective studies are needed to understand better the impact of low ALT genotypes on serum biochemical screening and monitoring for dogs with hepatic necroinflammatory disease. Until more studies are conducted, screening for this genotype may be considered in all dogs with discordant hepatic histologic and biochemical results. This case also illustrates the need for additional clinically available biomarkers for hepatic necroinflammatory conditions, such as CuCH in the dog.
The patient data used and/or analyzed during the current study are available in anonymized format from the corresponding author upon reasonable request.
copper-associated chronic hepatopathy
Center SA. Interpretation of liver enzymes. Vet Clin North Am Small Anim Pract. 2007;37(2):297–333. vii.
Lawrence YA, Steiner JM. Laboratory evaluation of the liver. Vet Clin North Am Small Anim Pract. 2017;47(3):539–53.
Johnston AN, Center SA, McDonough SP, Wakshlag JJ, Warner KL. Hepatic copper concentrations in Labrador Retrievers with and without chronic hepatitis: 72 cases (1980–2010). J Am Vet Med Assoc. 2013;242(3):372–80.
Webster CRL, Center SA, Cullen JM, Penninck DG, Richter KP, Twedt DC, et al. ACVIM consensus statement on the diagnosis and treatment of chronic hepatitis in dogs. J Vet Intern Med. 2019;33(3):1173–200.
Forman OP, Boursnell MEG, Dunmore BJ, Stendall N, van den Sluis B, Fretwell N, et al. Characterization of the COMMD1 (MURR1) mutation causing copper toxicosis in Bedlington terriers. Anim Genet. 2005;36(6):497–501.
van De Sluis B, Rothuizen J, Pearson PL, van Oost BA, Wijmenga C. Identification of a new copper metabolism gene by positional cloning in a purebred dog population. Hum Mol Genet. 2002;11(2):165–73.
Fieten H, Gill Y, Martin AJ, Concilli M, Dirksen K, van Steenbeek FG, et al. The Menkes and Wilson disease genes counteract in copper toxicosis in Labrador retrievers: a new canine model for copper-metabolism disorders. Dis Model Mech. 2016;9(1):25–38.
White ME, Hayward JJ, Stokol T, Boyko AR. Genetic mapping of novel loci affecting canine blood phenotypes. PLoS ONE. 2015;10(12):e0145199.
Thorsrud JA, Huson HJ. Description of breed ancestry and genetic health traits in arctic sled dog breeds. Canine Med Genet. 2021;8(1):8.
Raghu C, Ekena J, Cullen JM, Webb CB, Trepanier LA. Evaluation of potential serum biomarkers of hepatic fibrosis and necroinflammatory activity in dogs with liver disease. J Vet Intern Med. 2018;32(3):1009–18.
White ME, GENETIC MAPPING OF NOVEL LOCI AFFECTING CLINICAL PHENOTYPES OF THE DOMESTIC DOG, AND CAT. 2019 Aug 30 [cited 2022 Nov 11]; Available from: https://ecommons.cornell.edu/handle/1813/67781.
Thornburg LP, Shaw D, Dolan M, Raisbeck M, Crawford S, Dennis GL, et al. Hereditary copper toxicosis in West Highland white terriers. Vet Pathol. 1986;23(2):148–54.
Thornburg LP, Rottinghaus G, Dennis G, Crawford S. The relationship between hepatic copper content and morphologic changes in the liver of West Highland White Terriers. Vet Pathol. 1996;33(6):656–61.
Twedt DC, Sternlieb I, Gilbertson SR. Clinical, morphologic, and chemical studies on copper toxicosis of Bedlington Terriers. J Am Vet Med Assoc. 1979;175(3):269–75.
Rodrigues A, Leal RO, Girod M, Dally C, Guery E, Gomes E, et al. Canine copper-associated hepatitis: a retrospective study of 17 clinical cases. Open Vet J. 2020;10(2):128–34.
Poldervaart J, Favier R p., Van Den Penning L Ingh T s. g. a. m., Rothuizen J. Primary Hepatitis in Dogs: A Retrospective Review (2002–2006). Journal of Veterinary Internal Medicine. 2009;23(1):72–80.
Dirksen K, Verzijl T, Grinwis GC, Favier RP, Penning LC, Burgener IA, et al. Use of serum MicroRNAs as Biomarker for Hepatobiliary Diseases in Dogs. J Vet Intern Med. 2016;30(6):1816–23.
Dirksen K, Verzijl T, van den Ingh TSGa, Vernooij M, van der Laan JCM, Burgener LJWIA, et al. Hepatocyte-derived microRNAs as sensitive serum biomarkers of hepatocellular injury in Labrador retrievers. Vet J. 2016;211:75–81.
Koenig EM, Fisher C, Bernard H, Wolenski FS, Gerrein J, Carsillo M, et al. The beagle dog MicroRNA tissue atlas: identifying translatable biomarkers of organ toxicity. BMC Genomics. 2016;17:649.
Oosthuyzen W, Ten Berg PWL, Francis B, Campbell S, Macklin V, Milne E, et al. Sensitivity and specificity of microRNA-122 for liver disease in dogs. J Vet Intern Med. 2018;32(5):1637–44.
We thank Dr. Teena Price for her pathology expertise and for providing photomicrographs. We also thank Seth Peng for his logistical support.
The authors declare no competing interests.
Ethics approval and consent to participate
This patient was clinically managed with the standard of care for the treatment of CuCH in dogs based on the literature currently available. All treatments were provided by a licensed veterinarian. Informed owner consent was obtained prior to all diagnostic testing and treatments provided to the patient. No ethics approval was required.
Consent for publication
Informed consent for publication was obtained from the dog’s owner.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Kim, C., Loftus, J.P. & Huson, H.J. Low alanine aminotransferase activity gene variant in a Siberian Husky with copper-associated hepatopathy. BMC Vet Res 19, 111 (2023). https://doi.org/10.1186/s12917-023-03681-6
- Copper-associated hepatopathy
- Alanine aminotransferase
- Chronic hepatopathy